Literature DB >> 29846911

Correction to: Ibalizumab: First Global Approval.

Anthony Markham1.   

Abstract

The article Ibalizumab: First Global Approval, written by Anthony Markham, was originally published Online First without open access.

Entities:  

Year:  2018        PMID: 29846911      PMCID: PMC5993838          DOI: 10.1007/s40265-018-0926-2

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


Correction to: Drugs 78(7):781–785 (2018) 10.1007/s40265-018-0907-5

The article Ibalizumab: First Global Approval, written by Anthony Markham, was originally published Online First without open access. After publication in volume 78, issue 7, pages 781–785 Theratechnologies Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Theratechnologies Inc. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The original article was corrected.
  2 in total

1.  Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits.

Authors:  Nancy L Tumba; Gavin R Owen; Mark A Killick; Maria A Papathanasopoulos
Journal:  Vaccine X       Date:  2022-09-30

Review 2.  Injectable Antiretroviral Drugs: Back to the Future.

Authors:  Marco Berruti; Niccolò Riccardi; Diana Canetti; Sergio Lo Caputo; Lucia Taramasso; Antonio Di Biagio
Journal:  Viruses       Date:  2021-02-02       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.